<DOC>
	<DOCNO>NCT00788606</DOCNO>
	<brief_summary>This study evaluate use standard treatment R-CHOP plus anti-VEGF drug , bevacizumab whether treatment feasible patient stage II , III IV diffuse large B cell lymphoma ( DLBCL ) .</brief_summary>
	<brief_title>R-CHOP-B Bevacizumab Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description>Non-Hodgkin 's lymphoma increase incidence 287,000 case world-wide 9000 case UK diagnose year . DLBCL frequently occur NHL , constitute approximately 31 % non-Hodgkin 's lymphoma . Rituximab-CHOP chemotherapy show clinical efficacy regard standard treatment patient DLBCL . NICE recently approve use rituzimab combination CHOP newly diagnose patient DLBCL stage II-IV . Angiogenesis play important role pathophysiology solid tumour hematologic malignancy . Vascular endothelial growth factor ( VEGF ) important pro-angiogenic factor involve normal pathologic angiogenesis study also implicate VEGF lymphomagenesis . Elevated VEGF gene expression correlate diffuse large B cell lymphoma subtypes poor prognosis microarray analysis . In patient lymphoma , high circulate serum VEGF level strongly associate poor clinical outcome independent predictive factor . Bevacizumab humanize monoclonal antibody bind VEGF thus prevent bind receptor thus inhibit downstream pathway dependent receptor stimulation . Bevacizamab show activity solid tumour ( colorectal , renal , breast non-small cell lung cancer ) early result suggest combination R-CHOP plus bevacizamab feasible patient non Hodgkin 's lymphoma . Patients treat minimum 6 cycle treatment . A 2 cycle , total 8 cycle , may administer continue response treatment document residual disease still detectable restaging 6 cycle . Each cycle treatment 21 day . Follow - ) Clinic visit physical examination 3 , 6 , 9 , 12 , 18 24 month completion R-CHOP-B , annually . b ) CT scan chest , abdomen pelvis 3 month 1 year finishing treatment .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age &gt; 18 year . Histological proven diffuse large B cell nonHodgkin 's lymphoma ( DLBCL ) accord World Health Organization classification include morphological variant . The B cell nature proliferation must verify positivity antiCD20 antibody . All histology reveiwed central Lymphoma Trials Office pathology panel . No previous chemotherapy , radiotherapy investigational drug indication . Stage II , III IV disease . WHO performance status 0 &lt; 2 . Adequate bone marrow function platelet &gt; 100x109/l : neutrophil &gt; 1.5x109/l time study entry unless attribute bone marrow infiltration lymphoma . Serum creatinine &lt; 150μmol/l , serum bilirubin &lt; 35μmol/l transaminase &lt; 2.5 x upper limit institutional normal range unless attribute lymphoma . Normal MUGA echocardiogram without area abnormal contractility . Patients must acceptable left ventricular ejection fraction ( LVEF ) &gt; 50 % . No current uncontrolled medical condition . No active malignant disease basal squamous cell carcinoma skin carcinoma situ uterine cervix last 10 year . Adequate contraceptive precaution patient childbearing potential . Written , inform consent . Tcell lymphoma transform follicular lymphoma . Previous history treat nontreated indolent lymphoma . However , patient previously diagnose large Bcell lymphoma small cell infiltration bone marrow lymph node may include . Past history heart failure uncontrolled angina pectoris . Central nervous system , meningeal involvement cord compresssion lymphoma Cardiac contraindication doxorubicin ( abnormal contractility echocardiography nuclear medicine examination [ MUGA ] ) Neurological contraindication vincristine ( e.g preexist diabetic neuropathy ) . Any serious active disease General status allow administration 8 course CHOP accord investigator Positive serology HIV , Hepatitis B Hepatitis C Medical psychiatric condition compromise patient 's ability give inform consent Bevacuzumab relate criterion : No major surgery , major trauma open biopsy within 28 day prior study entry . Patients require insertion central venous access treatment ( e.g due poor venous access ) procedure perform least 2 day start treatment . No serious , nonhealing would , ulcer bone fracture . Absence obvious risk require emergency surgery commencement study treatmene , impend bowel obstruction . Absense clinically significant ( i.e active ) cardiovascular disease e.g . cerebrovascular accident ( &lt; 6 month prior randomisation ) , myocardial infarction ( &lt; 1 year prior randomisation ) , uncontrolled hypertension receive chronic medication , unstable angina , New York Hearth Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhymia require medication . No recent history active gastrointestinal inflammatory condition peptic ulcer disease , diverticulitis inflammatory bowel disease . If patient know diagnosis , evidence disease control require negative endoscopy within last 28 day . No evidence bleed disthesis coagulopathy . No recent commencement full oral anticoagulation ( warfarin ) , unless stable within therapeutic range least 10 day . No thrombolytic therapy within 10 day prior commencement study treatment . No chronic , daily treatment highdose aspirin ( &gt; 325mg/day ) nonsteroidal antiinflammatory medication ( know inhibit platelet function dos use treat chronic inflammatory disease ) . No chronic treatment corticosteriods ( dose . 10 mg/day methylprednisolone equivalent ) ( exclude inhale steroid ) . No known allergy Chinese hamster ovary cell protein recombinant human humanize antibody excipients bevacizumab formulation , platinum compound component study drug . No proteinuria baseline define &gt; 1g protein/24 hr 24hour urine collection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>diffuse large B cell lymphoma , DLBCL , R-Chop , bevacizumab</keyword>
	<keyword>Diffuse large B-cell non-Hodgkin 's lymphoma .</keyword>
</DOC>